Nasdaq
$48.44▼ 0.13%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.31BShares out 47.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 3d agoPre-market26.10.22 21:254Ownership#●●●
MBX Biosciences, Inc.
Insider Peter Radovich of MBX Biosciences reported a change in beneficial ownership of securities effective October 20, 2026. This filing is a standard disclosure of insider equity transactions via Form 4.…more
$48.44-0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoPre-market26.10.22 21:203Ownership
MBX Biosciences, Inc.
Peter Radovich, an officer of MBX Biosciences, has executed a Power of Attorney to authorize designated individuals to file SEC reports on his behalf. This document grants authority to handle filings such as Form 3, 4, 5, and Schedule 13D/13G in his capacity as an officer, director, or securityholder.…more
$48.44-0.13%vs prev closeView filingShare - 3d agoPre-market26.10.22 21:118-KKey event
MBX Biosciences, Inc.
MBX Biosciences appointed Peter Radovich as an independent director, effective October 20, 2026. He will serve until the 2028 Annual Meeting of Stockholders and will receive a non-qualified stock option to purchase 18,200 shares of common stock as part of his compensation.…more
$48.44-0.13%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13Pre-market26.10.13 21:00#●●●#●●●
MBX Biosciences to Participate in Upcoming November Investor Conferences…more
MBX Biosciences announced that its executive team will participate in several healthcare investor conferences throughout November. The management will engage in fireside chats and one-on-one meetings to discuss the company's clinical pipeline and business strategy.…more
$48.44-0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.9Pre-market26.09.09 21:00
●●●●●●●● ●●●●● ●●●●●●
MBX Biosciences announced that its executive team will participate in upcoming investor conferences hosted by Morgan Stanley and Stifel. These sessions will focus on company updates, though they represent routine investor relations activities.…more
$48.44-0.13%vs prev close - 8.27Pre-market26.08.27 21:00
●●●●●●●● ●●●●● ●●●●●●
MBX Biosciences has initiated its pivotal Phase 3 clinical trial for canvuparatide, a once-weekly treatment for chronic hypoparathyroidism. The study will enroll approximately 160 patients to evaluate the drug's efficacy and safety as a potential best-in-class therapy.…more
$48.44-0.13%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report